Brief: Capricor Therapeutics And Nippon Shinyaku Enter Partnership For Exclusive Commercialization And Distribution Of Cap-1002 For The Treatment Of Duchenne Muscular Dystrophy In Japan
16/02/2023 14:45
Feb 16 (Reuters) - CAPRICOR THERAPEUTICS INC CAPR.O :
* CAPRICOR THERAPEUTICS AND NIPPON SHINYAKU ENTER PARTNERSHIP FOR EXCLUSIVE
COMMERCIALIZATION AND DISTRIBUTION OF CAP-1002 FOR THE TREATMENT OF DUCHENNE
MUSCULAR DYSTROPHY IN JAPAN
* CAPRICOR THERAPEUTICS INC- CAPRICOR TO RECEIVE AN UPFRONT PAYMENT OF $12
MILLION
* CAPRICOR THERAPEUTICS INC- CAPRICOR WILL HOLD MARKETING AUTHORIZATION IN
JAPAN,
IF PRODUCT IS APPROVED IN THAT TERRITORY
* CAPRICOR THERAPEUTICS - CAPRICOR TO RECEIVE PAYMENTS OF UP TO $89 MILLION
AS
WELL AS MEANINGFUL DOUBLE-DIGIT PERCENTAGE OF REVENUE BASED ON PRODUCT SALES
Source text for Eikon: ID:nGNX7nMBFj
Further company coverage: CAPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nippon Shinyaku
See all newsTable: Nippon Shinyaku -Q1 group results (IFRS)
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)